Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Refresh the Infotainment Framework in the Volvo XC40 - 2Which Countries Would Suffer Most in a Global Energy Shutdown? This Study Has Answers
- 3April's full moon decides the date of Easter — here's how it works
- 4Zelensky sees win for Ukraine as EU finally reaches funding deal
- 5Invigorating Spots To Go Kayaking All over The Planet
- The 20 Most sultry Style of the Time
- New subclade K flu strain raises concerns: What families should know
- Two Endangered Bengal Tiger Cubs Die Days Apart at Zoo After Contracting Virus
- Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF
- Let them eat (Taylor Swift) cake: The baker turning A-listers into life-size desserts
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
- Becoming the best at Discussion: Individual Procedures
- How to disinfect if the stomach bug hits your home
- 41 Young Men Die in South Africa After Circumcision Initiation
